Ventricular Tachycardia - Pipeline Review, H2 2018

Publisher Name :
Date: 09-Oct-2018
No. of pages: 44
Inquire Before Buying

Ventricular Tachycardia - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Pipeline Review, H2 2018, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape.

Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain and shortness of breath. Causes include cardiomyopathy, ischemic heart disease and heart failure. Risk factors include age, family history and medical history. Treatment includes antiarrhythmic medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventricular Tachycardia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ventricular Tachycardia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventricular Tachycardia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 2, 1 and 4 respectively.

Ventricular Tachycardia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ventricular Tachycardia (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Ventricular Tachycardia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Ventricular Tachycardia (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Ventricular Tachycardia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Ventricular Tachycardia (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Ventricular Tachycardia (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Ventricular Tachycardia (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Ventricular Tachycardia - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ventricular Tachycardia - Overview
Ventricular Tachycardia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Ventricular Tachycardia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ventricular Tachycardia - Companies Involved in Therapeutics Development
Audentes Therapeutics Inc
Gilead Sciences Inc
HUYA Bioscience International LLC
InCarda Therapeutics Inc
Milestone Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Ventricular Tachycardia - Drug Profiles
AT-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budiodarone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etripamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
flecainide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-967 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBI-3000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
landiolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Tachycardia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FKBP1A for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ventricular Tachycardia - Dormant Projects
Ventricular Tachycardia - Discontinued Products
Ventricular Tachycardia - Product Development Milestones
Featured News & Press Releases
Aug 08, 2018: Milestone Pharmaceuticals announces first patient randomized in the phase 3 NODE-301 clinical trial evaluating Etripamil for termination of paroxysmal supraventricular tachycardia (PSVT) episodes
May 11, 2017: Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia
Apr 12, 2017: Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society's 38th Annual Scientific Sessions
Mar 07, 2017: Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer
Aug 31, 2016: InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias
Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia
Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND
Nov 24, 2014: Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients
Oct 28, 2013: Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Ventricular Tachycardia, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Ventricular Tachycardia - Pipeline by Audentes Therapeutics Inc, H2 2018
Ventricular Tachycardia - Pipeline by Gilead Sciences Inc, H2 2018
Ventricular Tachycardia - Pipeline by HUYA Bioscience International LLC, H2 2018
Ventricular Tachycardia - Pipeline by InCarda Therapeutics Inc, H2 2018
Ventricular Tachycardia - Pipeline by Milestone Pharmaceuticals Inc, H2 2018
Ventricular Tachycardia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
Ventricular Tachycardia - Dormant Projects, H2 2018
Ventricular Tachycardia - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Ventricular Tachycardia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Atorvastatin Market Insights, Forecast to 2025
    Published: 15-Feb-2019        Price: US 3900 Onwards        Pages: 117
    The global Atorvastatin market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Atorvastatin market based on company, product type, end user and key regions. This report studies the global market size of Atorvastatin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on......
  • Simvastatin - Global Market Research and Forecast, 2015-2025
    Published: 14-Feb-2019        Price: US 2200 Onwards        Pages: 71
    Summary The Simvastatin report provides an independent information about the Simvastatin industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent development. The report would be based on industry data clearly referenced from authentic and re......
  • Global Myocardial Ischemia Drugs Market Insights, Forecast to 2025
    Published: 06-Feb-2019        Price: US 3900 Onwards        Pages: 112
    The global Myocardial Ischemia Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Myocardial Ischemia Drugs market based on company, product type, end user and key regions. This report studies the global market size of Myocardial Ischemia Drugs in key regions like North America, Europe, Asia Pacific, Central & South Ameri......
  • Angina Pectoris Drugs Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 04-Feb-2019        Price: US 3000 Onwards        Pages: 148
    Angina Pectoris Drugs Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Angina Pectoris Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Angina Pectoris Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese ......
  • Global Rosuvastatin Calcium Market Status and Future Forecast 2015-2024
    Published: 03-Feb-2019        Price: US 4500 Onwards        Pages: 161
    Summary Key Content of Chapters (Including and can be customized) Part 1: Market Overview, Development, and Segment by Type, Application & Region Part 2: Global Market by company, Type, Application & Geography Part 3-4: Asia-Pacific Market by company, Type, Application & Geography Part 5-6: Europe Market by company, Type, Application & Geography Part 7-8: North America Market by company, Type, Application & Geography Part 9-10: South Ameri......
  • Hypotension - Pipeline Review, H1 2019
    Published: 31-Jan-2019        Price: US 2000 Onwards        Pages: 50
    Hypotension - Pipeline Review, H1 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension - Pipeline Review, H1 2019, provides an overview of the Hypotension (Cardiovascular) pipeline landscape. Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms i......
  • Thromboembolism - Pipeline Review, H1 2019
    Published: 31-Jan-2019        Price: US 2000 Onwards        Pages: 106
    Thromboembolism - Pipeline Review, H1 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H1 2019, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape. When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the che......
  • Left Ventricular Dysfunction - Pipeline Review, H1 2019
    Published: 31-Jan-2019        Price: US 2000 Onwards        Pages: 44
    Left Ventricular Dysfunction - Pipeline Review, H1 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Left Ventricular Dysfunction - Pipeline Review, H1 2019, provides an overview of the Left Ventricular Dysfunction (Cardiovascular) pipeline landscape. Left ventricular dysfunction is the most common cause of congestive heart failure. Symptoms include fluid retention, dizziness, fatigue, weakness, irregular heart......
  • Dilated Cardiomyopathy - Pipeline Review, H1 2019
    Published: 31-Jan-2019        Price: US 2000 Onwards        Pages: 70
    Dilated Cardiomyopathy - Pipeline Review, H1 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2019, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape. Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and we......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs